Follow the NeuroBo Pharmaceuticals, Inc. stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Market capitalisation: €2.2bn. The latest transaction was filed on 20 September 2024 (Cession). Among the most active insiders: DONG-A ST CO., LTD. All data is accessible without an account.
22
Insider Decl.
n/a
Thresholds
€17m
2 ops.
Buy Volume
€1,378
1 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate NeuroBo Pharmaceuticals, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$59.30.
30Σ signal
Buys €17m€1,378 Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
NeuroBo Pharmaceuticals, Inc. es una empresa biofarmacéutica centrada en el desarrollo de tratamientos para enfermedades neurodegenerativas. Emplea enfoques innovadores para mejorar la calidad de vida de los pacientes.